Press releases

11 November 2015

Paper demonstrating that RPL554 enhances CTFR activation in cystic fibrosis airway epithelia published in American Journal of Physiology

11 November 2015, Cardiff – Verona Pharma plc (AIM: VRP.L), the drug development company focused on first-in-class medicines to treat respiratory diseases, announces that a paper examining the effect of Verona Pharma’s dual PDE3/4 inhibitor, RPL554, on the Cys…

Read more

5 November 2015

Completion of patient enrolment in two RPL554 Phase IIa studies, ahead of expected timeline

Headline data expected in Q1 2016 and Q2 2016 5 November 2015, Cardiff – Verona Pharma plc (AIM: VRP.L), the drug development company focused on first-in-class medicines to treat respiratory diseases, today announces it has completed patient enrolment for the P…

Read more

14 October 2015

Start of RPL554 Phase IIa combination study

First COPD patients dosed with RPL554 on top of salbutamol and ipratropium Headline data expected Q2 2016 14 October 2015, Cardiff – Verona Pharma plc (AIM: VRP.L), the drug development company focused on first-in-class medicines to treat respiratory diseases,…

Read more

8 October 2015

Data demonstrating PDE3/4 inhibitor RPL554 enhances CTFR-dependent currents in cystic fibrosis airway epithelia

Poster presented at North American Cystic Fibrosis Conference, USA 8 October 2015, Cardiff – Verona Pharma plc (AIM: VRP.L), the drug development company focused on first-in-class medicines to treat respiratory diseases, announces that a poster will be presente…

Read more

29 September 2015

Positive headline data from RPL554 clinical study in COPD patients

New suspension formulation is well tolerated; results signal marked improvement in lung function RPL554 remains on track for entry into Phase IIb clinical trials in 2H 2016 29 September 2015, Cardiff – Verona Pharma plc (AIM: VRP.L), the drug development compan…

Read more

11 June 2015

RPL554 Phase 2a trial started; headline data expected Q1 2016

First asthma patients dosed with RPL554 in new proprietary nebulised formulation 11 June 2015, Cardiff – Verona Pharma plc (AIM: VRP.L), the drug development company focused on first-in-class medicines to treat respiratory diseases, today announces that the first…

Read more

8 June 2015

RPL554 MAD study in healthy volunteers confirms excellent tolerability; dosing of COPD patients commences

Multiple ascending dose study of RPL554 in healthy volunteers completed successfully; excellent tolerability at all dose levels tested Results continue to support twice daily dosing regimen with new RPL554 formulation Up to 30 COPD patients to be treated in multipl…

Read more

23 March 2015

Interim results from new RPL554 trial demonstrates excellent drug tolerability even at highest dose

Single ascending dose study in 50 healthy volunteers up to a dose that was 16 times greater than the previously used bronchodilator dose Well tolerated without an effect on cardio-vascular parameters and without nausea or vomiting at any dose Results support twice…

Read more

12 January 2015

First patients successfully dosed in clinical trial with new commercially scalable formulation of nebulised RPL554

Bronchodilation to be assessed in addition to study’s primary aim of safety and tolerability Both healthy volunteers and COPD patients to be evaluated New formulation expected to enable delivery of higher dose of drug in shorter time Results available in second h…

Read more

Realising multiple value creation opportunities with a unique respiratory product RPL554

AGM presentation

27 June 2016

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Targeting unmet needs

210m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us